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CLINICAL DECISION MAKING BASED ON DATA FROM GDx:
ONE-YEAR OBSERVATIONS
BY James C. Bobrow, MD
ABSTRACT
Purpose: To determine whether information derived from the GDx scanning laser polarimeter aids in the clinical deci-
sion-making process for patients with various types of glaucoma.
Methods: Over a 4-month period, 342 consecutive patients with primary open-angle glaucoma, ocular hypertension,
angle-closure glaucoma, or secondary glaucomas or in whom the diagnosis of glaucoma was uncertain were evaluated
with the GDx scanning laser. After 1 year, 153 patients with glaucoma underwent GDx analysis again. Chart review
revealed that 42 of the 153 patients had a change in therapy as a result of the GDx evaluation combined with analysis of
visual fields, optic disc cupping, and intraocular pressure (IOP). Outcomes were then compared.
Results: The group who had a change in therapy had a higher average GDx number (51.5 ± 26.1 vs 37.0 ± 23.5 [P=.001])
at the initial visit and higher IOP (18.2 ± 4.6  vs 16.0 ± 3.2 mm Hg [P=.005]). In spite of a change in therapy, at an aver-
age of 344 days later, IOP was unchanged (18.3 ± 5.3 vs 15.7 ± 3.2 mm Hg [P=.001]) and GDx values in the altered ther-
apy group were higher than at baseline (57.3 ± 27.9 vs 36.7 ± 23.4 [P=.001]), although the differences within each group
did not achieve statistical significance. 
Conclusion: GDx analysis may be helpful in determining patients at risk for damage from glaucoma, even in eyes in
which cup-disc ratio and field loss have not progressed. Changing medications without significantly reducing IOP may
be insufficient to halt increases in GDx numbers and may indicate a need for more aggressive therapy.
Trans Am Ophthalmol Soc 2002;100:131-136
INTRODUCTION
Attempts to find an objective discriminant function to sep-
arate patients with glaucoma from those without glaucoma
have been thwarted by the redundancy of the visual system
and the crudeness of the measurement techniques that
have been used. Subjective testing has also suffered from
individual variation in attention, comprehension, and
motor function. Finally, intraocular pressure (IOP) has
proved to be of uncertain value in many patients.
The final common pathway for visual loss in the glau-
comas is reduction of the competency and number of
nerve fibers carrying information to the processing centers
in the lateral geniculate body and visual cortex. Thus, when
devices purporting to measure the thickness of these layers
were introduced, investigators studied the ability of these
devices to discriminate between glaucomatous and
nonglaucomatous eyes. The result has been a spate of stud-
ies defining the specificity and sensitivity of each system to
separate the affected eyes from normal eyes.
A more practical question now awaits the ophthalmologist
who seeks to use advanced methods such as nerve fiber
layer analysis: How does the information gained affect clin-
ical decision making? In an office setting in which some
patients are already receiving therapy for glaucoma, others
are being followed without medication because of a dis-
parate spectrum of abnormal findings, and still others are
discovered to have abnormal findings for the first time, it
would be helpful to know how the addition of measure-
ments from a nerve fiber layer analyzer affects the deci-
sion-making process and whether these decisions preserve
visual function.
Since glaucoma disturbs vision in most cases in a
stealthy and slow manner, the conclusions from a 1-year
study may be preliminary at best; however, before col-
leagues are encouraged to invest in expensive equipment,
it would be helpful to prove some benefit or demonstrate
an additional degree of confidence in judgment corrobo-
rated by this added information. 
METHODS
The author’s office acquired a GDx nerve fiber layer ana-
lyzer (Laser Diagnostic Technologies, San Diego,
California) in the fall of 2000. After a 2-month break-in peri-
od with instruction and training of the technical staff, repro-
ducibility and reliability were tested on a series of normal 
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subjects. Results indicated that values of the “number,” an
age-, sex-, and race-determined derivative of the area
under the receiver operating characteristic (ROC) curve,
were consistent.  Data collection began in December
2000. Since the study is retrospective, the decision was
made in December 2001 to analyze the first 342 consecu-
tive patients who had GDx measurements made between
December 20, 2000, and April 13, 2001. Patient records
were then reviewed to determine whether changes in
medications, laser procedures, or surgeries were advised
and what part the additional information from the GDx
measurement played in the decision to alter therapy.
Follow-up has continued until April 10, 2002, and includes
analysis of subsequent GDx measurements when available.
Complete ophthalmologic evaluation was obtained,
including refraction, slit-lamp biomicroscopy, applanation
tonometry, dilated fundus examination, stereo disc pho-
tography, and Humphrey visual field evaluation using the
Swedish Interactive Threshold Algorithm (SITA) and 30-2
program. Scanning laser polarimetry using the GDx  was
performed in all patients able to cooperate for the test and
in whom the test was indicated for the diagnosis of glau-
coma or to follow patients in whom the diagnosis had
already been established.  The data were obtained from
the study population, consisting of a series of 342 consec-
utive patients examined between December 20, 2000, and
April 13, 2001. An attempt was made to reexamine as
many patients as possible about 1 year after their original
enrollment. Of these individuals, 153 patients with a vari-
ety of glaucomas also underwent a second GDx analysis
about 1 year following their original examination.
All data were tabulated and transferred to Epiinfo
6.04d. Statistical analysis using analysis of variance
(ANOVA) methodology was performed, and results were
considered statistically significant when P values were <.05.
RESULTS
Table I shows the demographic characteristics of the
study population. The age, sex, and racial distribution
were indicative of the office population from which the
study subjects were drawn. A positive family history of
glaucoma was elicited in 94 (27.4%) of all patients. The
types of glaucoma treated are shown in Table II. Studies
were performed on patients with a spectrum of findings.
In some cases, the GDx measurement was taken to estab-
lish the diagnosis, in some to differentiate ocular hyper-
tension from glaucoma, and in others to determine
whether therapy was adequate to prevent further damage.
Of the 153 glaucoma patients who had a second GDx
analysis, 70 eyes of 42 patients were found to require a
change in therapy initiated at the time of the first visit. 
Table III includes the types of glaucoma represented
in the 153 patients who underwent a second GDx exami-
nation. The decision to change therapy was made on the
basis of IOP, visual field findings, and examination of the
optic disc; but the GDx data informed the clinical deci-
sion-making process. Table IV lists the other variables
measured that, taken with the GDx readings, resulted in a
change in therapy. 
Table V includes the data at baseline for the factors tabu-
lated for each patient. The average IOP is consistent with a
population well controlled with therapy. Visual acuities ranged
from 20/15 to 20/200, since GDx measurements were found to
be difficult in patients with visual acuity reduced to less than
20/400, one-eyed patients, and those unable to 
fixate well enough for the 300 to 400 msec necessary to obtain
reliable means from three scans. In all patients for all exami-
nations, the reliability of the GDx averaged 
87% ± 6%. Low-reliability scans (<75%) were considered
unreadable and were not included in the study. The overall
failure rate gradually improved over the course of the first year
but averaged less than 3% for the entire 17-month period.
Among the patients receiving therapy, the average
TABLE I: DEMOGRAPHICS OF STUDY POPULATION
Age 69.2 ± 15.6 yr
Male-female ratio 127:215
White vs nonwhite 91.9% vs 8.1%
Family history of glaucoma 27.4%
Bobrow
TABLE II: TYPES OF GLAUCOMA IN STUDY POPULATION
TYPE OF GLAUCOMA NO. OF PATIENTS NO. OF EYES




Ocular hypertension 67 133
Pigmentary 18 36
Congenital 3 5
Diagnostic testing 10 20
Total 342 674
TABLE III: TYPES OF GLAUCOMA IN PATIENTS WHO UNDERWENT
A SECOND GDX MEASUREMENT AT 1 YEAR









number of medications used was 1.5 ± 0.7. No patient in
this study required surgery for uncontrolled glaucoma dur-
ing the year of observation, and only one eye was treated
with laser trabeculoplasty for uncontrolled IOP.
Table V also depicts the statistically significant differ-
ences noted between the eyes in which therapy was
changed and those in whom the current regimen was con-
tinued, including: (1) higher GDx number, (2) higher ini-
tial IOP, and (3) number of medications at the second
examination.
DISCUSSION
In an abstract presented at the 2002 annual meeting of the
Association for Research in Vision and Ophthalmology,
Choi and associates1 demonstrated that longitudinal analy-
sis over 25.9 months of retinal nerve fiber layer thickness
as measured with a scanning laser polarimeter reveals that
even when field loss has not progressed, the rate of thin-
ning of the nerve fiber layer is greater in patients with
open-angle glaucoma than in normal subjects.
Prior to this study, most of the published literature
focused on several other issues. At first, investigators 
concentrated on the reliability and reproducibility of the
various machines designed to measure nerve fiber layer
thickness. Zangwill and colleagues2 tried to distinguish
among the Heidelberg retina tomograph (HRT), the
GDx nerve fiber analyzer, and the optical coherence
tomograph (OCT). They found that, although the areas
under the ROC curves were similar, the OCT and HRT
had greater sensitivity. Colen and colleagues3 reported
that no significant differences appeared when both nor-
mal and glaucomatous patients were studied with the
three instruments.
The next phase in studying this equipment has been
to determine whether glaucoma patients may be discrim-
inated from normal patients or those with ocular hyper-
tension. Weinreb and coworkers4 used a variety of the
parameters from the GDx to study the detection of glau-
coma. They found an overall difference between the nor-
mals and patients with glaucoma but also considerable
overlap in parameters. Using three variables (average
thickness, ellipse modulation, and average ellipse thick-
ness), they generated a specificity of 92% and a sensitivity
of 74%. They felt that the software supplied with the GDx
did not perform as well as their selected parameters.
Lauande-Pimentel and associates5 performed a case-con-
trol study of GDx and visual field examinations together to
detect glaucoma. They found the information from the
GDx to be useful when added to other functional data. 
Paczka and colleagues6 compared various psy-
chophysical tests to the GDx and concluded that nerve
fiber layer photographs had high sensitivity values and fre-
quency-doubling perimetry had high specificity values,
but that GDx neural network parameters were almost as
sensitive and required less patient cooperation.
Poinoosawmy and coworkers7 tried to separate normal
TABLE V:  DIFFERENCES BETWEEN EYES WITH AND EYES WITHOUT A CHANGE IN THERAPY*
VARIABLE INITIAL VISIT SECOND VISIT
NO CHANGE CHANGE P VALUE NO CHANGE CHANGE P VALUE
GDx No. 37.0 ± 23.5 51.5 ± 26.1 .001 36.7 ± 23.4 57.3 ± 23.9 .001
Reliability (%) 88.6 ± 5.2 86.3 ± 5.5 .68 87.3 ± 5.6 88.7 ± 6.0 .56
IOP 16.0 ± 3.2 18.2 ± 4.6 .005 15.7 ± 3.1 18.3 ± 5.3 .001
Cup-disc ratio 0.51 ± 0.17 0.50 ± 0.19 .36 0.50 ± 0.18 0.52 ± 0.19 .54
Visual acuity (20/) 29.1 ± 17.4 38.9 ± 35.4 .08 28.1 ± 18.5 34.4 ± 27.8 .24
No. of medications 1.5 ± 0.6 1.5 ± 0.7 .88 1.5 ± 0.8 2.2 ± 0.7 .01
Days to second GDx 347 ± 66 341 ± 60 .42
IOP, intraocular pressure.
*Significant values are in bold type.
TABLE IV: FACTORS OTHER THAN GDX NUMBER THAT
INFLUENCED A CHANGE IN THERAPY
FACTOR NO. OF PATIENTS*
Intraocular pressure 24
Field loss 13
Increased cup-disc ratio 15
*42 patients required a change in therapy, but total is greater than 42
because some patients had multiple factors.
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patients from those with ocular hypertension and low-
pressure glaucoma by using the GDx. They found that the
number value determined by the intrinsic software sepa-
rated the low-tension glaucoma patients from the other
groups extremely well. They concluded that a close rela-
tionship exists between the parameters measured by scan-
ning laser polarimetry and disease severity. Sanchez-
Galeana and coworkers8 matched the various devices
measuring nerve fiber layer thickness against judgments
by two ophthalmologists and a vision scientist. They found
that no instrument alone was able to provide definitive
screening. Finally, Yamada and associates9 used the GDx
as a screening device and found that the GDx, when com-
pared to Humphrey perimetry (Fastpac 24-2 program),
separated normal patients from those with ocular hyper-
tension and glaucoma as well and could be performed
effectively on 98.5% of patients.
The practitioner who purchases a scanning laser
polarimeter or other device to measure nerve fiber layer
thickness has to rely on the data derived from examinations
and translated by the manufacturer into a user-friendly for-
mat. This study has attempted to use just the simplest param-
eter—the number, extrapolated from the ROC curve and
ratios of thickness of the superior and inferior nerve rim—to
follow two groups of patients: (1) those in whom a change in
therapy appeared to be indicated from the GDx measure-
ment and the other clinical parameters accumulated at the
time of the first examination and (2) those who seemed to be
well controlled with their then-current regimen. The num-
ber was chosen as the parameter to follow in these patients
because the manufacturer has communicated to prospective
purchasers that with this information, the examiner should
be able to distinguish those individuals with nerve fiber layer
loss from those with normal nerve thicknesses.10 As with all
new technologies, the specific measurements that are most
reliable have yet to be determined for this instrument. In
addition, the problem of corneal birefringence and its effect
on the repeatability and reliability of the GDx readings has
been called into question.11,12 It may be resolved by newer
technology that, according to the manufacturer, will be avail-
able in late 2002 (personal communication, Laser Diagnostic
Technologies, May 2002).  
The study has definite limitations because of its ret-
rospective nature; however, the intention to discriminate
between patients who needed a change in therapy and
those who did not might have affected the decision-
making process. The retrospective perspective may have
simulated the “in the trenches” mentality of the clinician
who evaluates each patient individually. 
All clinical data were collected by a single ophthal-
mologist and his staff experienced in obtaining IOPs and
visual fields. Since the GDx number is free from subjec-
tive interpretation except by the technician creating the
ellipse from which the nerve fiber layer thickness is calcu-
lated, and since each technician was similarly trained with
excellent interobserver agreement, this parameter should
not be subject to significant error. The cup-disc ratio is
subjective, but all patients had optic nerve stereophotog-
raphy that the author reviewed for consistency. 
The decision to alter therapy, armed with the data
available, represents the most subjective parameter.
Factors such as the patient’s ability to comprehend, com-
ply, and cooperate, as well as the establishment of an
appropriate “target pressure” for control of glaucoma, are
subjective at best. The fact that the groups differed in both
their initial data and their subsequent follow-up informa-
tion suggests that most of the poorly controlled patients
were detected and that the patients who continued with
their current regimen were well enough controlled, con-
sistent with the interpretation that the GDx may be both
sensitive and specific. The groups differ in that those who
required a change in therapy had higher GDx numbers
and higher IOP. Thus, the GDx either supported or con-
firmed that a change in therapy was indicated. In addition,
the data demonstrate that the group in whom therapy was
changed did not have an increase in IOP, an increase in
cup-disc ratio, or further visual field loss in the 341-day
interval between examinations. The difference in the mean
GDx number (51.5 ± 26.1 initially and 57.3 ± 23.9 at the
second visit) for this group, although averaging 5.8 points
higher, was not statistically significant.
None of the 42 patients whose medications were
changed had significant enough alterations in clinical
parameters during the 1-year interval to warrant additional
changes in therapy, laser procedure, or surgical interven-
tion. Longer follow-up will be necessary to accumulate
measurements sufficient to perfect this hypothesis, and
during that interval, the equipment will improve to enable
viewing the nerve fiber layer in greater detail with improve-
ments especially to minimize corneal birefringence. The
fact that only 58% of glaucoma patients had second GDx
measurements within the time limits established reduces
the power of the data to distinguish between the groups;
however, the demographic characteristics of the group who
had second GDx analyses are not statistically different from
those of the total group, including approximately the same
distribution in sex, race, age, and type of glaucoma.
CONCLUSION
The GDx can be used clinically in association with the
other time-honored measurements of glaucoma—visual
field loss, IOP, and cup-disc ratio—to separate controlled
from uncontrolled glaucoma. The inclusion of GDx data
may result in increased sensitivity to subtle changes in
optic nerve fiber layer deterioration prior to changes in
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the other parameters and prevention of subsequent func-
tional loss of vision. The GDx machine reduces depend-
ence on tests that require longer periods of concentration
and attention. Finally, normative data may be less helpful
than serial data in a single eye acting as its own control.
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DISCUSSION
DR ROBERT RITCH. Dr Bobrow has performed a retrospec-
tive chart review using the GDx nerve fiber layer analyzer
on 342 consecutive patients, 153 of whom underwent a 
second GDx examination approximately 1 year after the
first one. The purpose was to determine if the information
acquired influenced patient care by affecting the decision-
making process and whether these decisions preserved
visual function. Patient records were reviewed to deter-
mine whether changes in medications, laser procedures, or
surgeries were advised and what part the additional infor-
mation from the GDx played in the decision to alter therapy.
Parameters in addition to the GDx taken into account in
changing therapy included intraocular pressure, visual field
loss, and an increase in cupping. The eyes in which therapy
was changed had a higher mean GDx number, a higher
mean initial pressure, and were receiving a greater mean
number of medications. Each of these factors is associated
with more severe disease, which could make it more likely
that a patient would require a change in treatment. 
The problem with a retrospective study is the difficulty
in determining the consistency of the criteria on which
decisions were based. It is not clear what relative role the
GDx played in decision making nor whether any decisions
were based solely on GDx data. We do not know how much
weight was given to the GDx number in the decision-
making. The optimal GDx criteria to establish the diagnosis
of glaucoma or to determine whether therapy is adequate
to prevent further damage have yet to be determined.
Thus, the conclusion that the GDx can be used clinically in
association with other measures to separate controlled from
uncontrolled glaucoma still remains unsubstantiated.
A serious problem with the GDx is the effect of
corneal birefringence on the retinal nerve fiber layer thick-
ness assessment.1-4 The wide distribution of corneal bire-
fringence values observed in normal and glaucomatous
eyes suggests that the narrow-band corneal compensator
employed by the GDx is inappropriately compensating for
anterior segment birefringence in most eyes and limits the
discriminating power of the device. Many GDx parameters
are heavily biased by the presence of corneal birefringence
artifact, particularly integral and average measurements.
Dr Bobrow has taken the first step in understanding the
utility of this new technology in clinical practice. 
A study to evaluate a device like the GDx requires a
prospective design with specific well-defined end points,
such as criteria for scan quality, definitions of normal or
abnormal scans, repeated imaging to validate results, and
defined hypotheses on which to base decisions. The recent
development of a variable corneal compensator could
prove to be a significant advance, allowing diagnosis of
early disease and tracking of glaucoma progression.5
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DR DOUGLAS R. ANDERSON.  The hypothesis put to the test
with this review is “Which of these various factors–intraoc-
ular pressure, increased cupping, and GDx–were used by
the clinicians in reaching the decision to alter therapy”? A
multivariant analysis rather than single analyses might have
answered the question. Once IOP, for example, has been
taken into account, what additional variables added to the
decision to add therapy or not? Did the GDx number
come up with a statistically significant coefficient? 
DR JAMES C. BOBROW. In response to Dr Ritch’s com-
ments, this novel piece of equipment has become available
commercial only recently. The scientific underpinnings
may have faults; but I felt that it would be helpful to look
retrospectively at my own decision making experience, not
on a multivariable or quantitative basis, but to see my “gut-
level” results. No patient had a change in therapy unless
another parameter plus the GDx was altered in some way,
as you can see from the results I presented. The weight
given to the GDx, therefore, was confirmatory. I think the
value in the study, is simply that, one year later, the
changes in the GDx reflected the level of control of the
patient’s glaucoma. Since I had previously demonstrated
that the test was reliable in each individual when repeated,
I felt that the changes were significant even if the com-
pensator for corneal birefringence was not utilized (and it
has been promised for late 2002 for those who already own
the machines.  
As far as the need for a prospective study, I agree.  I
will be following these patients in a prospective fashion for
at least another year.  In glaucoma, as we all know, trends
emerge slowly.  Lastly, I want to comment that, just as cer-
tain parameters such as Mean Deviation scores from
Humphrey Field Analyzer (Zeiss: San Leandro, CA) have
been shown to be significant after clinical use, I think that
we will find that some of the individual ratios and inter-
mediate calculations in the GDx algorithm will be much
more helpful than the “number” that has been commer-
cially derived.
